文章基本信息

标题：New drugs in acute myeloid leukemia
本地全文：下载
作者：Theo de Witte ; Stefan Suciu ; Sergio Amadori 等
期刊名称：Drugs and Cell Therapies in Hematology
印刷版ISSN：2281-4876
出版年度：2014
卷号：2
期号：2
页码：86-88
出版社：PAGEPress Publications
摘要：Intensive chemotherapy regimens with or without stem cell transplantation are the current standard treatment in patients with acute myeloid leukemia (AML). The identifi- cation of new mutations in AML may provide the basis for a more targeted therapeutic approach. In one or several genetic subsets, some new drugs, as single drug or in com- bination with s tandard antileukemic drugs, demonstrated promising results. Typical ex- amples are tyros ine kinase inhibitors, such as dasatinib for f c-Kit mutated core binding factor positive AML or FLT-3 inhibitors, such as midostaur in or sorafenib, in cases with FLT-3 mutations. Clofarabine is a second generation hybrid pur ine nucleoside ana- logue: standard induction regimens containing clofarabine provided a high remission rates in patients with intermediate and high r is k AML. In patients unf it for intensive che- motherapy, treatment with hypomethilating agents is widely used. Gemtuzumab ozo- gamicin, anti-CD33 monoclonal antibody conjugated to calicheamicin, has shown signif icant antileukemic activity in older patients with relapsed AML
关键词：Acute myeloid leukemia; ; chemoterapy; targeted therapy; clo- ; farabine; hypomethilating agents; gen- ; tuzumab ozogamicin